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ABSTRACT 
Objective: The present investigation aimed towards the strain improvement of lovastatin maximum yielding wild-type fungal strains (Aspergillus 
terreus-MTCC 11045, Aspergillus terreus-MTCC 11395 and Aspergillus flavus-MTCC 11396) through physical mutagenesis by applying UV random 
mutations.  
Methods: Revival of fungal cultures on PDA plates followed by a screening of their morphological and microscopic properties. Strain improvement 
of screened fungi by UV (255 nm) random mutagenesis, selection of mutants based on morphological variations further submerged fermentation of 
selected (SmF) mutants, subsequently extraction of lovastatin from the spent broth and the extracts were analyzed for the presence of lovastatin by 
TLC and UV spectrophotometer scans (200-300 nm).  
Results: Out of eighteen screened mutant samples seven showed positive results for the lovastatin production. Among these seven positive 
cultures, Aspergillus terreus 11045-90 found to yield the maximum amount of lovastatin (3912 mg/l). 
Conclusion: The present study concludes by reporting the evidence of raised in the lovastatin titre by three-fold compared to the yield of the wild-
type strain (996 mg/l) and confirms the achievement of strain improvement by UV random mutagenesis.  
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INTRODUCTION 
In vivo studies of the human cholesterol, biosynthetic pathway 
reported that the enzyme 3-hydroxy-3-methyl glutaryl coenzyme A 
reductase (or) HMG Co A reductase, a rate-limiting enzyme of the 
cholesterol biosynthesis pathway was competitively inhibited by the 
drug lovastatin [1]. Human and animal in vitro trails of the drug 
lovastatin demonstrated a strong inhibitory activity on HMG Co-A 
reductase (rate limiting enzyme) of the cholesterol biosynthesis 
pathway. The inhibitory activity of the lovastatin on HMG Co-A 
reductase was found to reduce the overall cholesterol levels in the 
human plasma [2]. The HMG Co-A reductase inhibition by the 
lovastatin possess many beneficial health effects. Lovastatin is used 
along with a proper diet to help lower bad cholesterol, fats (such 
as LDL, triglycerides) and raise good cholesterol (HDL) in the blood. 
Lowering bad cholesterol, triglycerides and raising good cholesterol 
decreases the risk of heart disease and helps in preventing strokes 
and 
The filamentous fungus belongs to Aspergillus spp., i.e. Aspergillus 
terreus, Aspergillus flavus and Aspergillus oryzae were the well-
known producers of the drug lovastatin [9]. Lovastatin isolated from 
Aspergillus terreus was the first statin to be approved by FDA in 
1987 for therapeutic use [10]. Various fermentation methods such 
as liquid surface fermentation technique [11], submerged state 
fermentation (SmF) technique [12, 13] and solid state fermentation 
techniques [14, 15] were employed for the production of lovastatin. 
Media optimization studies of the (SmF) process have been carried 
out for the enhanced production of lovastatin by many researchers 
[16, 17]. Many researchers were attempted to isolate lovastatin over 
producing natural strains. A novel rapid screening method was 
employed based on the bioassay of lovastatin against the yeast 
Candida albicans for the isolation of lovastatin over producing 
strains of Aspergillus terreus [18]. Lovastatin maximum producing 
natural strains were isolated by screening the inhibitory activity of 
produced lovastatin on the fungi Neurospora crassa [8]. Scanty 
report was documented on the strain improvement methodologies 
to improve the efficacy of lovastatin production by natural fungi. 
Lovastatin hyper producing mutants of Aspergillus terreus was 
developed by applying cyclic mutagenesis approach [19] and 
through physical (UV light) and chemical (ethyl methane 
sulphonate) mutagenesis methods [20].  
heart attacks [3]. Lovastatin was found to be effective in 
treatments of cancer by suppressing cellular proliferation; inducing 
apoptosis and necrosis in experimentally induced various cancer cell 
lines [4, 5]. The therapeutic application of lovastatin in hastening 
repair of human fractures was studied at the preclinical stage by 
Olivera et al., and suggested that the lovastatin administered in a 
nanobead preparation enhances healing of human fractures [6]. 
Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte 
migration and attenuates experimental autoimmune encephalo-
myelitis [7]. Lovastatin was used in the preventive treatment of 
hypercholesterolemia, Parkinson’s disease, Alzheimer’s disease and 
atherosclerosis [8]. 
The present investigation focuses on adaptation of strain 
improvement methodologies using UV random mutagenesis method 
on the lovastatin maximum yielding wild-type fungal strains 
(Aspergillus terreus-MTCC 11045, Aspergillus terreus-MTCC 11395 
and Aspergillus flavus-MTCC 11396) isolated from the natural source 
by Upendra et al., [8] and were improved through random mutations 
by exposing to ultra-violet (UV) radiations at different time 
intervals. Initially preserved fungal cultures of Aspergillus terreus-
MTCC 11045, Aspergillus terreus-MTCC 11395 and Aspergillus flavus-
MTCC 11396 were revived on PDA and screened their 
morphological and microscopic characters. The screened fungi were 
exposed to UV rays at 255 nm for the different time intervals (15, 30, 
60, 90, 120 and 150 min). The morphological characteristics of the 
VU exposed strains were compared with wild-type stains and the 
variable strains were selected for SmF production of lovastatin. 
Selected UV mutated strains were grown under SmF, followed by 
downstream processing to extract the secondary metabolite 
lovastatin. The extracts were qualitatively analyzed by TLC, UV 
spectrophotometer scans (200-300 nm); Seven out of the eighteen 
screened mutant samples were showed positive results for the 
lovastatin. Aspergillus terreus 11045-90 yield the maximum amount 
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of lovastatin (3912 mg/l) followed by Aspergillus terreus 11395-90 
(3441 mg/l), Aspergillus terreus 11395-120 (3057 mg/l), Aspergillus 
terreus 11045-120 (2680 mg/l), Aspergillus terreus 11045-150 
(2378 mg/l), Aspergillus flavus 11396-90 (1916 mg/l) and 
Aspergillus flavus 11396-120 (1577 mg/l). The present study 
concludes by reporting the evidence on a rise in the lovastatin titre 
by three folds compare to the yield of the wild-type strain (0.996 
mg/l) and confirms the achievement of improved strain by UV 
random mutations.  
MATERIALS AND METHODS 
All the chemicals and reagents used during this study were of 
analytical grade (Merck, India). 
Screening of selected microorganism 
The culture of newly identified strain [21-24]; Aspergillus terreus-
MTCC 11045, Aspergillus terreus-MTCC 11395 and Aspergillus flavus-
MTCC 11396 were obtained from microbial type culture collection 
(IMTech-Chandigarh) and host cultures were revived on the potato 
dextrose agar (PDA) slants and stored at 4 °C. Further, all the three 
revived fungal isolates were cultured on four different media i. e 
potato dextrose agar (PDA) medium, yeast extract mannitol agar 
medium (YEMA), low carbon agar medium (LCA), and czapek dox 
agar medium (CZA). The fully grown cultures of all the selected 
fungal isolates were studied morphologically (form, margin, 
elevation, surface, texture and color) and microscopically (hyphae 
type, conidia size, shape and color) using light microscopy at 100 X 
magnification applying fungal specific lactophenol cotton blue 
staining method [8]. 
Strain improvement by physical mutagenesis  
The spores were collected from the screened strains grown on PDA 
slants by washing in sterile distilled water, and the spore count was 
carried using hemocytometer. Further, spore suspension was 
diluted to 1×105 spores/ml using phosphate buffer (pH-7). 4 ml of 
diluted spore suspension (each isolate separately) was aseptically 
transferred to 8 mm flat-bottom sterile petriplates and were 
exposed to UV radiations at 255 nm in different time intervals (15, 
30, 60, 90, 120 and 150 min) with gentle shaking. The UV exposed 
spore suspensions of selected fungal isolates were kept to a dark for 
overnight to avoid photoreactivation and subsequently grown on 
czapek dox medium at 28 o
The spores were collected from the selected mutants and were 
added to 50 ml of the seed culture medium (pH 6.8). The seed 
cultures were incubated in a rotary shaker incubator at 180 rpm at 
28 °C for 24 h. Ten percent of the seed broth was inoculated to 50 ml 
of production medium and incubated in a rotary shaker incubator at 
180 rpm at 28 °C for 10 d. Production media (composition per litre: 
glucose 50g, yeast extract 20g, tomato paste 30g, oat meal 20g, 
sodium acetate 10g, ammonium sulphate 5g, potassium dihydrogen 
phosphate 2g and trace element stock solution 10 ml (same as seed 
media) and distilled water 1 litre (pH 7.0) adjusted using 1M NaOH 
[8, 25]. 
Cfor 5-7 d [20]. 
Screening and selection of mutants 
The fully grown UV exposed cultures were screened and compared 
morphologically with that of wild strains, and the mutated strains 
were selected for the SmF process. 
Submerged fermentation of mutant strains  
Downstream processing of lovastatin 
At the end of fermentation, the broth was acidified to pH 3.0 with 10 
% 1N HCl and extracted with ethyl acetate @ 1:1 ratio for two hrs 
maintaining standard condition (180 RPM and 70 o
Screening of selected microorganism 
C temperature). 
By using Whatman No.40 filter paper, the fungal biomass was 
separated, and the filtrates were centrifuged at 3000xg for 10 min. 
To the collected organic phase 1% trifluoroacetic acid was added @ 
1:10 ratio to facilitate the lactonization process. Then the extract 
was concentrated at 80 °C (without vacuum), diluted to 1 ml with 
acetonitrile and filtered through a 0.45-μm filter for qualitative 
estimation by TLC and qualitative, quantitative estimation by UV 
spectrometry [8].  
Qualitative analysis of lovastatin by thin layer chromatography 
1.5 ml of collected organic phase was, concentrated to about 50 µl 
using a block heater adjusted to 45 °C and applied to a pre-activated 
20 X 20 cm Merck silica gel 60F254 TLC plates (Art No. 1.05554). 
The mobile phase used was dichloromethane and ethyl acetate 
(70:30, v/v). The lovastatin stock standard was prepared from the 
pure lactone form of the compound and dissolved in acetonitrile (3 
mg/ml) which was then mixed in a test tube in equal proportion and 
was used as working standard. Standards and pre-concentrated 
samples were spotted on TLC plate and allow it to dry for 30 min 
and further developed three times in mobile phase. After the ¾th 
distance of the run the plates were observed under a hand-held UV 
lamp (254 nm) or stained with iodine vapor to compare the spots of 
both the standard and extracted samples [26]. 
UV spectrophotometric analysis of lovastatin 
The presence of lovastatin in a prepared sample was qualitatively 
analyzed using UV spectrometric scan (shimadzu, model no UV-2450 
and software UV-probe 2.21) between 200 nm–300 nm and 
subsequently estimated at 238 nm, using pure lovastatin (Biocon 
laboratories, Bangalore, India) as a standard [27, 28].  
RESULTS  
Morphologic and microscopic screening of the selected fungal 
cultures is an important parameter to assess the growth stability 
and purity of the revived fungal cultures. The morphological 
properties of newly identified strain; Aspergillus terreus-MTCC 
11045, Aspergillus terreus-MTCC 11395 and Aspergillus flavus-MTCC 
11396 cultured on PDA medium was discussed at-the-table 1. 
  
Table 1: Morphological screening of selected fungal strains cultured on PDA media 
Fungal strain Morphological characters 
Form Margin Elevation Surface texture Colour 
Aspergillus terreus-MTCC 11045 Filamentous Entire Pulvinate Dry and Powdery Light Brown 
Aspergillus terreus-MTCC 11395 Filamentous Unduled Pulvinate Dry and Powdery Light Brown 
Aspergillus flavus-MTCC 11396 Filamentous Entire Raised Dry and Powdery Light Yellow with Greenish 
Tinge 
 
The microscopic studies of the selected fungi explained that the 
Aspergillus terreus 11045 and Aspergillus terreus 11395 were 
similar with hyaline, septate hyphae and smooth, elliptical conidia 
forms long chains with biseriate phialides, Aspergillus flavus 
11396 shows smooth, elliptical conidia form long chains biseriate 
phialides, extending from the upper portion of the vehicle.  
The results explained that the revived cultures selected for the 
strain improvement methodologies were of pure in culture and 
steady in growth. 
Screening and selection of mutants (UV random mutagenesis) 
The UV exposed spore suspensions of selected fungal isolates were 
grown on czapek dox medium, and the fully grown mutants were 
selected based on their morphological variation with respect to the 
wild-type strains fig. 1. 
Submerged fermentation and downstream processing of lovastatin 
The spores of UV exposed fungal cultures were grown under 
submerged fermentation conditions to screen their potential for 
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lovastatin production. At the end of 10 d of fermentation, the 
acidified fermentation broth was extracted for the lovastatin. 
Extracts of lovastatin from the SmF cultures of mutants was taken 
for the analysis of lovastatin. 
  
 
Fig. 1: The UV exposed cultures of Aspergillus terreus-MTCC 11045, Aspergillus terreus-MTCC 11395 and Aspergillus flavus-MTCC 11396 
grown on czapek dox medium 
 
Table 2: Rf Values comparison of standard lovastatin with UV-exposed fungal SmF extracts 
 Wild-type strain UV exposure duration (in min) Mutant code number Rf value 
1.  Aspergillus terreus-MTCC 11045 90 A. terreus 11045-90 0.86 
2.  120 A. terreus 11045-120 0.86 
3.  150 A. terreus 11045-150 0.86 
4.  Aspergillus terreus-MTCC 110395 90 A. terreus 11395-90 0.86 
5.  120 A. terreus 11395-120 0.86 
6.  Aspergillus terreus-MTCC 110396 90 A. flavus 11396-90 0.86 
7.  120 A. flavus 11396-90 0.86 
8.  Standard Lovastatin - - 0.86 
 
Qualitative analysis of lovastatin by thin layer chromatography 
Once the run was completed, the separated solute spots were 
developed with iodine vapors and the results reported that among 
the 18 SmF extracts studied in TLC, 7 were shown spots on a TLC 
plate and their Rf values were found to be similar with the standard 




Fig. 2: UV spectrophotometric analysis of lovastatin, 2A): Line 
graph representing the absorbance maxima (238 nm) of the 
positive lovastatin mutants, 2B): Bar graph representing the 
absorbance of the lovastatin positive mutated strains at 
different UV wavelengths 
 
A. terreus 11045-90 yield the maximum amount of lovastatin (3.912 
mg/l) followed by A. terreus 11395-90 (3.441 mg/l), A. terreus 11395-
120 (3.057 mg/l), A. terreus 11045-120 (2.68 mg/l), A. terreus 11045-
150 (2.378 mg/l), A. flavus 11396-90 (1.916 mg/l) and A. flavus 11396-
120 (1.577 mg/l) in the screening work through SmF process (fig. 3). 
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UV spectrophotometric analysis of lovastatin 
The concentration of lovastatin was calculated spectro-
photometrically (in triplicates). The samples (5 ml) and the standard 
exhibited a peak at 238 nm in the spectrophotometer scanning (fig. 
2). The results reported that among the 18 cultures screened a total 
of seven fungal cultures were showed positive results for lovastatin 
production. 
 
Fig. 3: Bar graph of the concentration of lovastatin produced by 
the fungal mutants 
 
Lovastatin standard concentrations [S1-0.2 mg/ml, S2-0.4 mg/ml, 
S3-0.6 mg/ml, S4-0.8 mg/ml, S5-1.0 mg/ml, S6-1.2 mg/ml], 
lovastatin concentration of SmF samples [A. terreus 11395-120 
(3.057 mg/ml), A. terreus 11396-90 (1.916 mg/ml), A. terreus 
11045-90 (3.912 mg/ml),  
A. terreus 11045-150 (2.372 mg/ml), A. terreus 11045-120 (2.68 
mg/ml), A. terreus 11395-90 (3.441 mg/ml), A. flavus 11396-120 
(1.577 mg/ml)]. Error bars were omitted for simple presentation. 
DISCUSSION 
In the present study, attempts were made to improve the lovastatin 
maximum yielding wild-type fungi to enhance the yield of lovastatin 
further. Initially, all the three preserved fungal cultures were 
revived, and their morphological and microscopic characters were 
screened. The screened fungi were exposed to UV rays at 255 nm for 
the different time intervals (15, 30, 60, 90, 120 and 150 min) with 
gentle shaking. The mutants were selected based on morphological 
variations and were grown under SmF, followed by downstream 
processing to extract the metabolite lovastatin. The extracts were 
qualitatively analyzed by TLC, UV spectrophotometer scan (200-300 
nm); 7 out of the 18 screened mutants samples were showed 
positive results for the productions of lovastatin. Aspergillus terreus 
11045-90 yield the maximum amount of lovastatin (3912 mg/l) 
followed by Aspergillus terreus 11395-90 (3441 mg/l), Aspergillus 
terreus 11395-120 (3057 mg/l), Aspergillus terreus 11045-120 
(2680 mg/l), Aspergillus terreus 11045-150 (2378 mg/l), Aspergillus 
flavus 11396-90 (1916 mg/l) and Aspergillus flavus 11396-120 
(1577 mg/l). The yield reported by the mutant strain developed in 
the present study Aspergillus terreus 11045-90 (3912 mg/l) was 4 
fold higher than the wild-type strain lovastatin yield (996 mg/l) [8]. 
A novel rapid screening method was demonstrated for isolation of 
lovastatin over producing stains of Aspergillus terreus. The screening 
methodology was based on the activity of lovastatin against the 
yeast Candida albicans. The study showed that the new 6-h assay 
had a linear correlation between the quantity of lovastatin 
generated by A. terreus isolates and the inhibition zone obtained on 
plates of C. albicans [18]. The lovastatin yield reported in this study 
is very less compare to the enhanced yield of the present study 
(3912 mg/l). 134 fungal cultures were isolated from different soil 
samples and were screened for lovastatin production. The maximum 
lovastatin-producing strain (A. terreus strain GD13-190 mg/l) 
among the screened was selected and subjected to rational 
mutation-selection program based on the resistance to lovastatin 
and fatty acid synthase (FAS) inhibitors, viz., iodoacetamide and N-
ethyl-maleimide. The study reported that a hyper-producing mutant 
(EM19) exhibiting 7.5-fold (1424 mg/l) higher levels of lovastatin, 
which was approximately 3 fold lesser than the lovastatin yield 
reported in the present study [19]. A strain improvement study of A. 
terreus was carried out by physical and chemical mutagenesis for 
increased lovastatin production. Four mutant clones were obtained 
after physical mutagenesis, out of which two mutants were derived 
from UV irradiation and other two mutants from ethyl methyl 
sulfonate treatment. The yield of lovastatin varied from mutants to 
mutants and the mutant strain JPM3-UV1 produced the maximum 
lovastatin (1553 mg/ml), which was approximately 3 fold lesser 
than the lovastatin yield reported in the present study [20]. A soil 
fungal isolate Aspergillus terreus MTCC10831 was subjected to UV 
light followed by ethyl methyl sulfonate treatment for enhanced 
production of lovastatin. The best UV mutant SPUV002 exhibited 
lovastatin productivity of 32.78% higher than wild strain. The ethyl 
methyl sulfonates mutant SPEM142 had a yield of 663μg/ml of 
lovastatin. The result indicated that UV and ethyl methyl sulfonate 
were effective mutagenic agents for strain improvement of A. terreus 
MTCC10831 for enhanced production of lovastatin. The present 
study reported approximately 5 fold higher lovastatin yield 
compared to the yield of discussed study [29]. 
CONCLUSION 
Considering these references as discussed above, it could be 
concluded that Aspergillus terreus MTCC 11045-90, the improved 
fungal isolate was found to produce highest yield (3912 mg/l) of 
lovastatin. It can also be seen that the present investigation led to 
explore the physical mutagenesis (UV random mutation) technique 
for improving the lovastatin yielding efficiencies of wild-type fungal 
isolation.  
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